Expedition Therapeutics Inc. focuses on developing innovative therapies for diseases caused by RNA dysregulation. The company employs a proprietary platform that leverages small molecule drugs to target RNA-binding proteins, which play a crucial role in the regulation of gene expression. This approach aims to modulate the activity of these proteins, thereby restoring normal cellular function and addressing the underlying causes of various diseases, including cancer and neurodegenerative disorders. By harnessing the potential of RNA biology, Expedition Therapeutics seeks to create effective treatments that can significantly improve patient outcomes.

In addition to its small molecule drug development, Expedition Therapeutics is committed to advancing its understanding of RNA biology through rigorous scientific research. The company utilizes cutting-edge techniques in molecular biology and biochemistry to explore the interactions between RNA and proteins, which are essential for the development of its therapeutic candidates. This scientific foundation not only supports the discovery of new drug candidates but also enhances the company's ability to identify and validate novel targets for intervention, ultimately driving innovation in the field of RNA-targeted therapies.

US platform for in-licensing assets from China for global development. 

Uniquely positioned with expertise at the intersection of US and Chinese biotech innovation. Extensive knowledge and network of relationships with innovator companies across China; coupled with US track-record, capabilities, and top-tier investor support. Strong visibility into competitive landscape of both US and China biotech ecosystems enhances asset selection. 

Founding investors: Venrock, BVF and Lake Bleu.

Expedition Therapeutics Inc.

Company Details